-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Source: Yaodu Written by: Xiaoguang Editor: Maruko
1
Current status of myasthenia gravis treatment
Myasthenia gravis is a rare, chronic autoimmune disease caused by dysfunction of neuromuscular junction transmissio.Efgartigimod brings new breakthrough in MG treatment
Overview of the domestic distribution of FcRn inhibitors
FcRn becomes another potential blockbuster target in the field of autoimmunity2 Ushibi - rozanolixizumab
3 and Platinum Medicine/HanAll Biopharma - Bartolimumab
refer to:
https://https://FDA Approves Soliris® (Eculizumab) for the Treatment of Patients with Generalized Myasthenia Gravis (gM.
https:// ht.